AlexanderLesokhin MD

I am an oncologist @sloan_kettering who specializes in immunotherapy and the treatment of multiple myeloma. Tweets are mine.

[Urvi Shah @UrviShahMD]

Can dietary changes delay progression from precursor disorders to a cancer - myeloma? Excited to share our manuscript is published online @CD_AACR @MSKCancerCenter @SanRaffaeleMI @Bellone_lab @DrMvandenBrink @LesokhinMD @Lauracgr001 @szusmani #mmsm #ASH25

https://t.co/nWvY90Azgr

[Urvi Shah @UrviShahMD]

What happens to the microbiome in lenalidomide related diarrhea and are there foods that may mitigate it? Kevin Miller a hematology oncology fellow @MSK_DeptOfMed has done some excellent work to answer this Q. Do stop by our poster #ASH25 #mmsm @LesokhinMD @szusmani

[AlexanderLesokhin MD @LesokhinMD]

This is the opposite of great. Why do this??
https://t.co/reHYGa6PGF via @NYTimes

[Urvi Shah @UrviShahMD]

This project has been a wonderful collaboration & team science including @DrMvandenBrink @vandenBrinkLab @LesokhinMD @szusmani @Neil_Iyengar and mouse data from @Bellone_lab @Lauracgr001 @MSKCancerCenter and many others #mmsm
Look forward to presenting latest updates #ASH24

[Malin Hultcrantz MD PhD @MalinHultcrantz]

Colesevelam is highly effective and safe for treatment of lenalidomide associated diarrhea:
- Phase 2 trial, 25 pts
- 88% improved diarrhea
- 68% complete resolution
- No effect on lenalidomide PK
#mmsm @MSKCancerCenter @MSKHemOncTrials @BloodCancerJnl
https://t.co/KnMOE3tAG0

[AlexanderLesokhin MD @LesokhinMD]

via @NYTOpinion https://t.co/b8zVavkpTc

[AlexanderLesokhin MD @LesokhinMD]

@MSKCancerCenter @AbdelWahablab Congrats Omar! Well deserved!!
#ASH2023 (Anyone else curious about the music choice?)

[AlexanderLesokhin MD @LesokhinMD]

@WinshipAtEmory Congrats!! @AjayNookaMD

[AlexanderLesokhin MD @LesokhinMD]

@NBahlis @NatureMedicine @hollyleeYJ @FrancescoMaura4 @RascheLeo @PedalheadPHX @UCalgary @UCalgaryMed @Charb_Cancer Superb paper!

[Mohamad Mohty @Mohty_EBMT]

Thank you all for this smooth and important collaboration that lead to the approval of elranatamab by FDA @NatureMedicine @PfizerOncMed @LesokhinMD @NBahlis @AjayNookaMD @NoopurRajeMD @DrEmmaSearle @COMyCongress

[Saheli Sadanand @SaheliSadanand]

🌟Hot off the press in @NatureMedicine! The pivotal phase 2 MagnetisMM-3 trial of #Elranatamab in patients with r/r #MultipleMyeloma. This bispecific got accelerated approval from the FDA yesterday! @LesokhinMD @MSKCancerCenter @Mohty_EBMT @PfizerOncMed https://t.co/vWJyIqyBEH

[Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 @szusmani]

Congratulations @LesokhinMD @NoopurRajeMD and all colleagues involved with the studies #mmsm

[AlexanderLesokhin MD @LesokhinMD]

Another exciting approval for MM patients! Honored to have been a part from FIH to approval ⁦@MSKHemOncTrials⁩. ⁦@MSKCancerCenter.⁩ Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma | Pfizer https://t.co/meOeSIa4Ot

[AlexanderLesokhin MD @LesokhinMD]

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://t.co/bHmKTEQNp8

[Noopur Raje @NoopurRajeMD]

Sharing our consensus on this important topic @BloodCancerJnl @SagarLonialMD @mvmateos : Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: con… https://t.co/e92f8d9LBf

[AlexanderLesokhin MD @LesokhinMD]

via @NYTimes https://t.co/M7Na3u95h0

[AlexanderLesokhin MD @LesokhinMD]

@DmitriyZamarin Congrats!!

[AlexanderLesokhin MD @LesokhinMD]

@NBahlis Congrats! Awesome work!

[Urvi Shah @UrviShahMD]

Congratulations @kordeneha1 on presenting patient centric data from the maintenance cessation study in myeloma showing 12 month MRD negativity rate of 88% with stable trends in HRQoL @MSKCancerCenter #mmsm #ASH22 #ASHkudos

[AlexanderLesokhin MD @LesokhinMD]

@DrMatasar @RutgersCancer Congrats Matt!